Drug Interaction Potentiation

A Drug-Drug Interaction Study of Warfarin and PA21
NCT01477424 | PHASE 1 | INTERVENTIONAL

The purpose of this study is to determine if Warfarin is affected by PA21.

Trial Information
1 Sites
45 Participants
COMPLETED
20 Years to 50 Years

If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
PRA International Clinical Pharmacology Center
Lenexa,Kansas,United States,66219

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov